14th Nov 2016 16:20
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES |
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: | QUANTUM PHARMA PLC |
2 Reason for the notification (please tick the appropriate box or boxes): | ||
An acquisition or disposal of voting rights | Yes | |
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||
An event changing the breakdown of voting rights | ||
Other (please specify): |
| |
3. Full name of person(s) subject to the notification obligation: |
Harwood Capital LLP (as investment adviser/manager) and North Atlantic Smaller Companies Investment Trust plc |
4. Full name of shareholder(s) (if different from 3.): |
1. North Atlantic Smaller Companies Investment Trust PLC
2. Oryx International Growth Fund Limited
|
5. Date of the transaction and date on which the threshold is crossed or reached: | 11 NOVEMBER 2016 |
6. Date on which issuer notified: | 14 NOVEMBER 2016 |
7. Threshold(s) that is/are crossed or reached: |
ABOVE 14%
|
8. Notified details: | |||||||
A: Voting rights attached to shares | |||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | |||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights | |||
Direct | Direct | Indirect | Direct | Indirect | |||
Holder 1:
Holder 2:
| 3,921,158
10,000,000
|
3,921,158
10,000,000
|
10,000,000
15,000,000
|
10,000,000
15,000,000
|
5.91%
8.87%
|
B: Qualifying Financial Instruments | ||||
Resulting situation after the triggering transaction | ||||
Type of financialinstrument | Expirationdate | Exercise/ConversionPeriod | Number of votingrights that may beacquired if theinstrument isexercised/ converted.
| % of votingrights |
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||
Resulting situation after the triggering transaction | ||||||
Type of financialinstrument | Exerciseprice | Expirationdate | Exercise/Conversionperiod | Number of votingrights instrumentrefers to | % of voting rights
| |
Nominal | Delta
| |||||
Total (A+B+C) | |
Number of voting rights | Percentage of voting rights |
25,000,000 | 14.78% |
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: |
|
Proxy Voting: | |
10. Name of the proxy holder: | |
11. Number of voting rights proxy holder will cease to hold: | |
12. Date on which proxy holder will cease to hold voting rights: |
13. Additional information: | |
14. Contact name: | Jane Muir |
15. Contact telephone number: | 020 8819 6486 |
Related Shares:
Quantum Pharma